

**Chronic Kidney Disease (CKD)** affects an estimated 1 in 10 people globally, with current treatments unable to fully eliminate the risk of kidney failure.



In Aotearoa New Zealand, CKD affects 11% of the population, with higher prevalence among Māori (25%) and Pacific peoples (33%) due to complex social and geopolitical factors. CKD also occurs 10 years earlier in Māori and Pacific adults compared to non-Māori, non-Pacific adults.

CAPTIVATE is an **adaptive**, **platform-based**, **randomised** controlled trial that aims to find the best treatment, or combination of treatments, to slow kidney function decline. The **CAPTIVATE Australia New Zealand (ANZ) Consumer Engagement Committee** provides ongoing advice and guidance to the study, and was integral to its design. As the first platform trial in CKD, multiple treatments are tested simultaneously within a common trial setup. The adaptive design provides flexibility to add new treatments, or remove those that are not working.

Individuals aged **18 or older** with **CKD from any cause**, and a kidney function measured by **an eGFR of 25 or higher** (mL/min/1.73m²), may be eligible to participate. Participants may receive more than one treatment, either simultaneously or at different times. For each treatment, participants will be randomly assigned to receive either the active treatment, or a matching placebo (an inactive study pill). This process is called **randomisation**. Each treatment will last for 2 years, with study visits scheduled at 1, 3, 6, 12, 18, and 24 months after randomisation.

CAPTIVATE has started testing whether a **Mineralocorticoid Receptor Antagonist (MRA)** can slow the progression of CKD compared to a placebo. The study is being conducted globally; we are currently active in Australia, India and at sites in Aotearoa New Zealand.



## Scan the QR code or visit our website for more information:

https://www.georgeinstitute.org/ourresearch/research-projects/captivatefinding-treatments-to-slow-theprogression-of-chronic





## Interested in participation?

Contact your local GP, kidney specialist or local Clinical Trials Unit (CTU) to reach our study team. Visit <a href="https://www.medsafe.govt.nz/regulatory/CSSites.htm">https://www.medsafe.govt.nz/regulatory/CSSites.htm</a> for a list of certified CTU sites.